P80 Protein Treatment Method Using Pharmaceutical Composition Comprising Neurotoxin Associated Polypeptide
Summary
The USPTO published patent application US20260098066A1 assigned to Prime Bio, Inc., covering a method of treating disorders using a pharmaceutical composition comprising a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E. The p80 acts as a tight junction modulator to enhance intestinal epithelium permeability, facilitating drug delivery and increasing bioavailability of therapeutic agents including drugs, small molecules, proteins, and biomolecules.
What changed
The USPTO published a patent application disclosing a method of treating disorders by administering a pharmaceutical composition containing a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E. The p80 polypeptide is bound to therapeutic agents including drugs, dyes, small molecules, biomolecules, or proteins to enhance transportation into the bloodstream and increase bioavailability. The p80 functions as a tight junction modulator to enhance permeability of the intestinal epithelium, facilitating oral or topical drug delivery.
For pharmaceutical manufacturers and biotech companies developing drug delivery systems, this patent application represents potential prior art in the field of tight junction modulation for enhanced bioavailability. Entities should review their own pipeline candidates and delivery technologies to assess potential overlap. The composition's application in oral delivery of botulinum-derived polypeptides may also be relevant to developers of biologics and macromolecular therapeutics seeking improved bioavailability solutions.
What to do next
- Monitor for patent grant or office action response deadlines
- Review for prior art relevance to drug delivery compositions
- Assess freedom-to-operate implications if developing tight junction modulators
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of Treatment Using a Pharmaceutical Composition Comprising a p80 Protein
Application US20260098066A1 Kind: A1 Apr 09, 2026
Assignee
Prime Bio, Inc.
Inventors
Bal Ram Singh, Raj Kumar
Abstract
Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT/E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.
CPC Classifications
C07K 14/33 A61K 45/06 C07K 1/18 A61K 38/00
Filing Date
2025-10-07
Application No.
19352455
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.